Physician profile
Mark Freijat
NPI 1124337621
$9,646.71
in general payments reported to CMS, 2019-2025
33 companies · $2,342 in 2025
The $2,342 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.38 · 2021: $1,762 · 2022: $1,112 · 2023: $1,921 · 2024: $2,486 · 2025: $2,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,594 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,594.00 |
| Education | $155.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,263.20 | 2021-2025 | Tavneos, Enbrel, Krystexxa |
| Janssen Biotech, INC. | $931.79 | 2021-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $867.90 | 2021-2025 | Rinvoq, Skyrizi |
| Glaxosmithkline, LLC. | $864.49 | 2021-2025 | Benlysta |
| Ucb, INC. | $635.10 | 2022-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $466.09 | 2021-2023 | Krystexxa |
| Pfizer INC. | $448.68 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $436.64 | 2021-2025 | Orencia |
| Actelion Pharmaceuticals US, INC. | $409.69 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Sobi, INC | $356.18 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $312.11 | 2020-2025 | |
| Mallinckrodt Hospital Products INC. | $221.53 | 2024-2025 | Acthar |
| Lilly USA, LLC | $212.94 | 2022-2024 | Taltz |
| Astrazeneca Pharmaceuticals LP | $181.63 | 2022-2024 | Saphnelo, Flumist Quadrivalent |
| Akebia Therapeutics INC | $139.70 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $139.27 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $110.03 | 2022-2025 | Lupkynis |
| Sandoz INC. | $97.00 | 2023-2025 | Hyrimoz |
| Bayer Healthcare Pharmaceuticals INC. | $94.90 | 2023 | |
| Scilex Pharmaceuticals INC. | $53.03 | 2024 | |
| Genentech USA, INC. | $50.04 | 2023-2025 | Actemra |
| Mylan Institutional INC. | $49.94 | 2023 | Hulio |
| Biocon Biologics INC | $43.09 | 2024 | Hulio |
| Qiagen, LLC | $43.08 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.99 | 2024-2025 | |
| Celltrion USA INC. | $37.59 | 2023 | Yuflyma |
| Ferring Pharmaceuticals INC. | $30.27 | 2021 | |
| Almatica Pharma LLC | $24.18 | 2025 | Teriparatide |
| Grifols USA, LLC | $20.68 | 2025 | Gamunex-C |
| Oxford Immunotec USA INC | $19.64 | 2021 | |
| Nalu Medical, INC. | $18.37 | 2025 | Nalu Neurostimulation System |
| Tersera Therapeutics LLC | $16.92 | 2025 | Quzyttir |
| Avanos Medical | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Freijat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.